New York, NY – September 07, 2011 – Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.
Source: Original Article